MX367338B - Uso de cannabinoides para el tratamiento de epilepsia. - Google Patents

Uso de cannabinoides para el tratamiento de epilepsia.

Info

Publication number
MX367338B
MX367338B MX2016016459A MX2016016459A MX367338B MX 367338 B MX367338 B MX 367338B MX 2016016459 A MX2016016459 A MX 2016016459A MX 2016016459 A MX2016016459 A MX 2016016459A MX 367338 B MX367338 B MX 367338B
Authority
MX
Mexico
Prior art keywords
treatment
cbd
epilepsy
ert
disclosure relates
Prior art date
Application number
MX2016016459A
Other languages
English (en)
Other versions
MX2016016459A (es
Inventor
Guy Geoffrey
Wright Stephen
Mead Alice
Joshi Charuta
Wilfong Angus
Original Assignee
Gw Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51266718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367338(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gw Pharma Ltd filed Critical Gw Pharma Ltd
Publication of MX2016016459A publication Critical patent/MX2016016459A/es
Publication of MX367338B publication Critical patent/MX367338B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente divulgación se refiere al uso de canabidiol (CBD) para la reducción de la frecuencia total de ataques convulsivos en el tratamiento de ``epilepsia resistente al tratamiento´´ (TRE). En particular, la divulgación se refiere al uso de CBD para tratar TRE cuando la TRE es síndrome de Dravet; crisis de ausencia mioclónica o síndrome de la epilepsia relacionado con infección febril (FIRES). La divulgación además se refiere al uso de CBD en combinación con uno o más fármacos antiepilépticos (los AED).
MX2016016459A 2014-06-17 2015-06-17 Uso de cannabinoides para el tratamiento de epilepsia. MX367338B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1410771.8A GB2530001B (en) 2014-06-17 2014-06-17 Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB1506550.1A GB2531093A (en) 2014-06-17 2015-04-17 Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
PCT/GB2015/051775 WO2015193667A1 (en) 2014-06-17 2015-06-17 Use of cannabinoids in the treatment of epilepsy

Publications (2)

Publication Number Publication Date
MX2016016459A MX2016016459A (es) 2017-04-06
MX367338B true MX367338B (es) 2019-08-15

Family

ID=51266718

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2016016460A MX373797B (es) 2014-06-17 2015-06-17 Uso de cannabidiol para el tratamiento de epilepsia.
MX2016016459A MX367338B (es) 2014-06-17 2015-06-17 Uso de cannabinoides para el tratamiento de epilepsia.
MX2020003182A MX391834B (es) 2014-06-17 2015-06-17 Uso de cannabidiol para el tratamiento de epilepsia.
MX2019008337A MX393712B (es) 2014-06-17 2015-06-17 Uso de cannabinoides para el tratamiento de epilepsia.
MX2022004851A MX2022004851A (es) 2014-06-17 2016-12-13 Uso de cannabidiol para el tratamiento de epilepsia.
MX2022008278A MX2022008278A (es) 2014-06-17 2016-12-13 Uso de cannabinoides para el tratamiento de epilepsia.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016016460A MX373797B (es) 2014-06-17 2015-06-17 Uso de cannabidiol para el tratamiento de epilepsia.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2020003182A MX391834B (es) 2014-06-17 2015-06-17 Uso de cannabidiol para el tratamiento de epilepsia.
MX2019008337A MX393712B (es) 2014-06-17 2015-06-17 Uso de cannabinoides para el tratamiento de epilepsia.
MX2022004851A MX2022004851A (es) 2014-06-17 2016-12-13 Uso de cannabidiol para el tratamiento de epilepsia.
MX2022008278A MX2022008278A (es) 2014-06-17 2016-12-13 Uso de cannabinoides para el tratamiento de epilepsia.

Country Status (11)

Country Link
US (18) US9474726B2 (es)
EP (2) EP3157512B1 (es)
JP (8) JP6655850B2 (es)
AU (8) AU2015275886A1 (es)
BR (2) BR112016029506A2 (es)
CA (3) CA2952994C (es)
ES (2) ES2680656T3 (es)
GB (2) GB2530001B (es)
MX (6) MX373797B (es)
PL (2) PL3157512T3 (es)
WO (2) WO2015193667A1 (es)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US12544389B2 (en) * 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
US11911361B2 (en) 2014-05-29 2024-02-27 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
CA2961410C (en) 2014-09-16 2023-07-11 India Globalization Capital, Inc. Cannabinoid composition and method for treating pain
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531280A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
US10675207B2 (en) * 2014-11-04 2020-06-09 A Better Walker, Llc Wrap around walking aid
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
CA2981285A1 (en) * 2015-04-01 2016-10-06 India Globalization Capital, Inc. Composition and method for treating seizure disorders
US20160317468A1 (en) * 2015-04-28 2016-11-03 Raman Sankar Uses of cannabidiol for treatment of infantile spasms
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
GB2548873B (en) * 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
EP3251668A1 (en) 2016-06-02 2017-12-06 Pharmotech SA Cannabidiol compositions and uses thereof
EP3471746A4 (en) 2016-06-15 2020-02-26 India Globalization Capital, Inc. METHOD AND COMPOSITION FOR TREATING CRAMPING SEASONS
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
EP4233861A3 (en) 2016-08-11 2023-10-11 Ovid Therapeutics, Inc. Compositions for treatment of essential tremor
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
JP2020514282A (ja) * 2016-12-20 2020-05-21 ティルレイ，インコーポレイティド 新規カンナビノイド組成物および使用方法
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
CA3062247A1 (en) * 2017-05-09 2018-11-15 Zogenix International Limited Methods of treating doose syndrome using fenfluramine
IL271149B2 (en) 2017-06-14 2024-05-01 Trevena Inc Compounds for modulating s1p1 activity and methods of using the same
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
US20190022028A1 (en) * 2017-07-21 2019-01-24 Annabelle Manalo Cannabidiol-enriched caprylic acid
BR112020004947A2 (pt) * 2017-09-19 2020-09-15 Zynerba Pharmaceuticals, Inc. canabidiol transdérmico sintético para o tratamento de epilepsia focal em adultos
WO2019067413A1 (en) * 2017-09-26 2019-04-04 Zogenix International Limited USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
GB201715919D0 (en) * 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568471B (en) * 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572737A (en) * 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3745884A1 (en) 2018-01-31 2020-12-09 Canopy Holdings, Llc Hemp powder
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
US20200009077A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Compositions for treating dermatological diseases
AU2019335372B2 (en) * 2018-09-05 2024-12-12 Purisys Llc Cannabidiol compositions having modified cannabinoid profiles
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
GB2579179A (en) * 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB2581517A (en) 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20250152520A2 (en) * 2019-03-08 2025-05-15 The Regents Of The University Of California Use of 8,9- dihydrocannabidiol compounds
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
AU2020341464A1 (en) * 2019-09-05 2022-04-21 Trevena, Inc. Methods of treating epilepsy using the same
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
GB2588461A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of absence epilepsy
EP4061352A4 (en) 2019-11-19 2024-02-28 Trevena, Inc. COMPOUNDS AND METHODS FOR PRODUCING S1P1-MODULATING COMPOUNDS
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201918846D0 (en) * 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
GB2597307A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with encephalitis
GB2597287A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597288A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597300A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597280A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with auriculotemporal syndrome
GB2597309A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597321A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597286A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes
GB2597299A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597308A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597283A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB2597282A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597316A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597302A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with stroke or brain haemorrhage
GB2597291A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597301A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
GB2597304A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with shaken baby syndrome
GB2597315A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597297A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
GB202013765D0 (en) 2020-09-02 2020-10-14 Gw Res Ltd Method of preparing cannabinoids
GB2598922A (en) * 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
JP2023552390A (ja) * 2020-12-03 2023-12-15 ジナーバ・ファーマシューティカルズ・インコーポレイテッド 難治性発作の治療
GB2602019A (en) 2020-12-15 2022-06-22 Gw Res Ltd Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
JP2024500611A (ja) 2020-12-23 2024-01-10 エム－フォー、エルエルシー カンナビノイドの抽出および精製
CN117479930A (zh) * 2021-04-08 2024-01-30 长矛治疗股份有限公司 用于治疗癫痫发作病症的药物组合物和方法
KR102800463B1 (ko) * 2021-04-27 2025-04-30 비조팹 주식회사 Ｃｂｄ 액상 조성물 제조 방법과 이를 함유하는 의료용 제품을 제공하는 텔레메디슨 시스템
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2024033521A1 (en) 2022-08-12 2024-02-15 GW Research Limited Oral solid dosage forms comprising cannabinoids
WO2025024009A1 (en) * 2023-07-24 2025-01-30 Poviva Corp. Compositions and methods for treating epilepsy
JP2025529608A (ja) * 2023-07-24 2025-09-09 ポビバ コーポレーション てんかんを処置する為の組成物及び方法
US11986485B1 (en) 2023-07-24 2024-05-21 Poviva Corp Compositions and methods for treating epilepsy
US11944635B1 (en) * 2023-07-24 2024-04-02 Poviva Corp Compositions and methods for treating epilepsy
US12023346B1 (en) 2023-07-24 2024-07-02 Poviva Corp Compositions and methods for treating epilepsy
US11931369B1 (en) 2023-07-24 2024-03-19 Poviva Corp Compositions and methods for treating epilepsy
KR20250071888A (ko) 2023-11-15 2025-05-22 강원대학교산학협력단 신규한 카나비디올 유도체, 이의 제조방법 및 이를 포함하는 뇌전증 치료용 약학 조성물
KR20250136252A (ko) 2024-03-07 2025-09-16 강원대학교산학협력단 카나비디올 유도체를 포함하는 뇌전증의 예방 또는 치료용 조성물

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2304669A (en) 1940-08-16 1942-12-08 Adams Roger Isolation of cannabidiol
JPS5430146A (en) 1977-08-05 1979-03-06 Microbial Chem Res Found Novel anthracycline derivatives and their preparation
GB9726916D0 (en) 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6403126B1 (en) 1999-05-26 2002-06-11 Websar Innovations Inc. Cannabinoid extraction method
US6949582B1 (en) 1999-05-27 2005-09-27 Wallace Walter H Method of relieving analgesia and reducing inflamation using a cannabinoid delivery topical liniment
IL136839A (en) 2000-06-16 2006-12-10 Yissum Res Dev Co Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same
DE10051427C1 (de) 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
GB2381194A (en) 2001-09-07 2003-04-30 Gw Pharmaceuticals Ltd Pharmaceutical formulations
DK1361864T3 (en) 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
US7025992B2 (en) 2001-02-14 2006-04-11 Gw Pharma Limited Pharmaceutical formulations
GB2377633A (en) 2001-05-11 2003-01-22 Gw Pharmaceuticals Ltd Pharmaceutical compositions comprising the cannabinoids THC and CBD
GB2380129B (en) 2001-02-14 2004-08-11 Gw Pharma Ltd Pharmaceutical formulations
ATE348097T1 (de) 2001-04-09 2007-01-15 Chiron Corp Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten
GB2377218A (en) 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
GB2381450B (en) 2001-10-31 2006-05-31 Gw Pharma Ltd Compositions for administration of natural or synthetic cannabinoids by vaporisation
GB0202385D0 (en) 2002-02-01 2002-03-20 Gw Pharma Ltd Compositions for the treatment of nausea,vomiting,emesis,motion sicknes or like conditions
ITPD20020138A1 (it) 2002-05-24 2003-11-24 Matteo Bevilacqua Composizione di sostanze a base terpenica, metodo di preparazione e metodo di dispersione in ambiente della medesima.
DE10226494A1 (de) 2002-06-14 2004-01-08 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
SI1542657T1 (sl) 2002-08-14 2012-04-30 Gw Pharma Ltd Kanabinoidne kapljevite formulacije za sluzniäśno administracijo
US10538373B2 (en) 2002-08-14 2020-01-21 Gw Pharma Limited Pharmaceutical formulation
DK2311475T3 (en) 2002-08-14 2016-09-19 Gw Pharma Ltd Extraction of pharmaceutically active cannabinoids FROM PLANT MATERIALS
GB0222077D0 (en) 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
GB2393182B (en) 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
US20040110828A1 (en) 2002-11-27 2004-06-10 Chowdhury Dipak K. Tetrahydrocannabinol compositions and methods of manufacture and use thereof
KR20060040676A (ko) 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
EP1680145A4 (en) * 2003-10-14 2007-05-23 Neurologix Res Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
IL160420A0 (en) 2004-02-16 2004-07-25 Yissum Res Dev Co Treating or preventing diabetes with cannabidiol
GB2414933B (en) 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
WO2006017892A1 (en) 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070060638A1 (en) 2005-08-26 2007-03-15 Olmstead Mary C Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist
WO2007032962A2 (en) 2005-09-09 2007-03-22 University Of Kentucky Compositions and methods for intranasal delivery of tricyclic cannabinoids
CN102766128A (zh) 2005-09-29 2012-11-07 阿尔巴尼分子研究公司 δ-9-四氢大麻酚的生成方法
GB2432312A (en) 2005-11-01 2007-05-23 Gw Pharma Ltd Pharmaceutical compositions for the treatment of pain
US9265724B2 (en) * 2005-11-07 2016-02-23 Ram B. Murty Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
GB2434312B (en) 2006-01-18 2011-06-29 Gw Pharma Ltd Cannabinoid-containing plant extracts as neuroprotective agents
WO2007142957A2 (en) 2006-05-30 2007-12-13 Air Systems Gear drive damper
GB2438682A (en) 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
WO2008019146A2 (en) 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
WO2008021394A2 (en) 2006-08-15 2008-02-21 Theraquest Biosciences, Llc Pharmaceutical formulations of cannabinoids and method of use
US20110150825A1 (en) 2006-11-14 2011-06-23 Pharmacyclics, Inc. Uses of selective inhibitors of hdac8 for treatment of inflammatory conditions
US20080188461A1 (en) 2007-02-01 2008-08-07 Regents Of The University Of Michigan Compositions and methods for detecting, preventing and treating seizures and seizure related disorders
CN101040855A (zh) 2007-04-12 2007-09-26 杨喜鸿 含有利莫那班和泊洛沙姆的组合物、固体分散体及其制备和药物应用
GB2448535A (en) 2007-04-19 2008-10-22 Gw Pharma Ltd New use for cannabinoid-containing plant extracts
US9084771B2 (en) 2007-05-17 2015-07-21 Sutter West Bay Hospitals Methods and compositions for treating cancer
GB2449691A (en) 2007-05-31 2008-12-03 Gw Pharma Ltd A reference plant lacking medicinal active compound expression
EP2023121A1 (en) 2007-07-06 2009-02-11 Bp Oil International Limited Optical cell
GB2450753B (en) 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
DK2176208T3 (en) 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
CA2698752A1 (en) 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
GB2456183A (en) 2008-01-04 2009-07-08 Gw Pharma Ltd Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB2459637B (en) 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
LT2280687T (lt) * 2008-03-26 2019-08-26 Stichting Sanammad Kramtomosios gumos kompozicijos, apimančios kanabinoidus
GB2478074B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
GB2478072B (en) 2008-06-04 2012-12-26 Gw Pharma Ltd Anti-tumoural effects of cannabinoid combinations
EP2341903A1 (en) 2008-07-31 2011-07-13 Bionorica Research GmbH Cannabinoids for use in treating or preventing cognitive impairment and dementia
WO2010031054A1 (en) * 2008-09-15 2010-03-18 Biovista, Inc. Compositions and methods for treating epilepsy
PL2352497T3 (pl) 2008-10-31 2017-08-31 University Of Mississippi Proces przygotowania estrów aminokwasowych delta-9-thc
MX2011011514A (es) 2009-04-28 2011-11-18 Alltranz Inc Formulaciones de canabidiol y metodos para utilizarlas.
MX2011011445A (es) 2009-04-29 2011-11-18 Univ Kentucky Res Found Composiciones que contienen cannabinoides y metodos para su uso.
BRPI1014139A2 (pt) 2009-06-29 2016-04-26 Bender Analytical Holding Bv sistema de liberação de fármacos compreendendo polioxazolina e um agente biotivo.
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
US8735374B2 (en) 2009-07-31 2014-05-27 Intelgenx Corp. Oral mucoadhesive dosage form
US20110033529A1 (en) 2009-08-06 2011-02-10 Durga Prasad Samantaray Oral pharmaceutical paricalcitol formulations
WO2011034920A1 (en) * 2009-09-16 2011-03-24 Allergan, Inc. Compositions and methods for treating seizure disorders
GB2478595B (en) 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
DE102010012281A1 (de) 2010-03-22 2011-09-22 Fresenius Medical Care Deutschland Gmbh Pharmazeutische Zusammensetzungen enthaltend substituiertes 6-Deoxy-6-sulfanylcyclodextrin
GB2479153B (en) 2010-03-30 2014-03-19 Gw Pharma Ltd The phytocannabinoid cannabidivarin (CBDV) for use in the treatment of epilepsy
GB2487183B (en) 2011-01-04 2018-10-03 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
CA2802047C (en) 2010-06-07 2019-05-07 Novadel Pharma Inc. Oral spray formulations and methods for administration of sildenafil
PE20131096A1 (es) 2010-08-04 2013-10-10 Gruenenthal Chemie Forma de dosificacion farmaceutica que comprende 6'-fluoro-(n-metil-o n,n-dimetil)-4-fenil-4',9-dihidro-3'h-espiro[ciclohxan-1,1'-pirano[3,4,b]indol]-4-amina para el tratamiento de dolor neuropatico
WO2012033478A1 (en) 2010-09-07 2012-03-15 Murty Pharmaceuticals, Inc. An improved oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US8895536B2 (en) * 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
WO2012071389A2 (en) * 2010-11-22 2012-05-31 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2487712B (en) * 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
CA2737447A1 (en) 2011-04-27 2012-10-27 Antony Paul Hornby Hayley's comet
US9104993B2 (en) 2011-04-28 2015-08-11 Lantronix, Inc. Asset management via virtual tunnels
GB2524689B (en) 2011-05-20 2016-01-27 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
GB201111261D0 (en) 2011-07-01 2011-08-17 Gw Pharma Ltd Cannabinoids for use in the treatment of neuro-degenerative diseases or disorders
US9750747B2 (en) 2011-08-26 2017-09-05 Bail-Portela & Ca, S.A. Treatments involving eslicarbazepine acetate or eslicarbazepine
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
GB2496687A (en) 2011-11-21 2013-05-22 Gw Pharma Ltd Tetrahydrocannabivarin (THCV) in the protection of pancreatic islet cells
US9254272B2 (en) 2011-11-30 2016-02-09 Sutter West Bay Hospitals Resorcinol derivatives
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
DE102012105063C5 (de) 2012-06-12 2023-09-14 Thc Pharm Gmbh The Health Concept Stabilisierung von Cannabinoiden und deren pharmazeutischen Zubereitungen
US9345771B2 (en) 2012-10-04 2016-05-24 Insys Development Company, Inc. Oral cannabinoid formulations
CN103110582A (zh) 2013-03-04 2013-05-22 上海医药工业研究院 大麻酚类化合物微乳剂及其制备方法
US9095554B2 (en) 2013-03-15 2015-08-04 Biotech Institute LLC Breeding, production, processing and use of specialty cannabis
HRP20200324T1 (hr) 2013-03-19 2020-06-12 Universitat Pompeu-Fabra Antagonisti kanabinoidnog receptora cb1 za upotrebu u liječenju bolesti povezanih s neuronalnim dendritičkim abnormalnostima
JP6300613B2 (ja) 2013-04-09 2018-03-28 キヤノン株式会社 トナー用樹脂およびトナー
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
LT3062606T (lt) 2013-10-29 2019-07-10 Biotech Institute, Llc Specializuotų kanapių selekcija, gamyba, perdirbimas ir panaudojimas
US20150181924A1 (en) * 2013-10-31 2015-07-02 Michael R. Llamas Cannabidiol liquid composition for smoking
US9259449B2 (en) 2014-01-07 2016-02-16 Joshua Michael Raderman Method for modifying THC content in a lipid-based extract of cannabis
US10052339B2 (en) * 2014-03-21 2018-08-21 Bodybio Inc. Methods and compositions for treating symptoms of diseases related to imbalance of essential fatty acids
CN103913888B (zh) 2014-03-28 2016-08-17 京东方科技集团股份有限公司 一种彩膜基板、显示装置及彩膜基板的制造方法
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
WO2015187988A1 (en) 2014-06-04 2015-12-10 Intellimedix Composition and methods of treating epilepsy and/or epilepsy-related disorders
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
US9822384B2 (en) 2014-07-14 2017-11-21 Librede Inc. Production of cannabinoids in yeast
US9492438B2 (en) 2014-07-25 2016-11-15 Bette Pollard Amphiphilic pyridinum compounds to treat epilepsy and other disorders of the nervous system
WO2016022936A1 (en) 2014-08-07 2016-02-11 Murty Pharmaceuticals, Inc. An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts
CA2859934A1 (en) 2014-09-22 2016-03-22 A. Paul Hornby Hayley's comet ii
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531280A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
CN107205960A (zh) 2014-10-21 2017-09-26 联合大麻公司 大麻提取物及其制备和使用方法
CN104490873A (zh) 2014-11-25 2015-04-08 邹丽萍 一种治疗儿童结节性硬化症的药物
WO2016084075A1 (en) 2014-11-26 2016-06-02 One World Cannabis Ltd Synergistic use of cannabis for treating multiple myeloma
US10172786B2 (en) 2014-12-16 2019-01-08 Axim Biotechnologies, Inc. Oral care composition comprising cannabinoids
CA2974895A1 (en) 2015-01-25 2016-07-28 India Globalization Capital, Inc. Composition and method for treating seizure disorders
HK1244715A1 (zh) 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US20160338974A1 (en) 2015-03-02 2016-11-24 Afgin Pharma, Llc Topical regional neuro affective therapy with cannabinoid combination products
WO2016147186A1 (en) 2015-03-19 2016-09-22 One World Cannabis Ltd Preparations of cannabis emulsions and methods thereof
US20160317468A1 (en) 2015-04-28 2016-11-03 Raman Sankar Uses of cannabidiol for treatment of infantile spasms
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
CA2986268C (en) 2015-05-28 2024-01-02 Insys Development Company, Inc. Stable cannabinoid formulations
US20180185324A1 (en) 2015-06-11 2018-07-05 One World Cannabis Ltd Novel cannabinoid combination therapies for multiple myeloma (mm)
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US20170008869A1 (en) 2015-07-10 2017-01-12 Noramco, Inc. Process for the production of cannabidiol and delta-9-tetrahydrocannabinol
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
AU2017212651B2 (en) 2016-01-29 2020-01-23 University Of Mississippi Biologically active cannabidiol analogs
WO2017139496A1 (en) 2016-02-09 2017-08-17 Cevolva Biotech, Inc. Microbial engineering for the production of cannabinoids and cannabinoid precursors
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
EP3462885A4 (en) 2016-05-27 2020-01-22 Insys Development Company, Inc. STABLE CANNABINOID FORMULATIONS
GB2551985B (en) 2016-07-01 2019-01-30 Gw Res Ltd Novel formulation
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
CN108236608B (zh) 2016-12-27 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与氨己烯酸的药物组合物及其用途
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
CA3062814C (en) 2017-04-27 2023-11-14 Insys Development Company, Inc. Stable cannabinoid formulations
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
IT201700085508A1 (it) 2017-07-26 2019-01-26 Inalco S R L Metodo per la produzione di cannabinoidi da varietà di canapa industriale
US10925525B2 (en) 2017-08-18 2021-02-23 Canon U.S.A., Inc. Combined pulse oximetry and diffusing wave spectroscopy system and control method therefor
GB201715919D0 (en) 2017-09-29 2017-11-15 Gw Res Ltd use of cannabinoids in the treatment of epilepsy
GB2568471B (en) 2017-11-15 2022-04-13 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US11498018B2 (en) 2017-11-27 2022-11-15 Vasilios (Bill) Panagiotakopoulos Extraction and purification of cannabinoid compounds
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
EP3732813A1 (en) 2017-12-29 2020-11-04 Telefonaktiebolaget LM Ericsson (publ) Methods providing transmission and/or searching of encrypted data and related devices
GB2572125B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2572126B (en) 2018-01-03 2021-01-13 Gw Res Ltd Pharmaceutical
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
GB2572737A (en) 2018-01-24 2019-10-16 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
GB2579179A (en) 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB2580881A (en) 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2580653A (en) 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
GB2581517A (en) 2019-02-22 2020-08-26 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2581987B (en) 2019-03-06 2021-11-17 Gw Res Ltd Use of cannabidiol in combination with antibiotics
GB2584140A (en) 2019-05-23 2020-11-25 Gw Res Ltd Use of cannabidiol in the treatment of epileptic spasms
GB2584341B (en) 2019-05-31 2023-03-01 Gw Res Ltd Cannabinoid formulations
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2586026A (en) 2019-07-29 2021-02-03 Gw Res Ltd Use of cannabidol in the treatment of Dravet syndrome
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB201916977D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannibidol-type cannabinoid compound
GB201918846D0 (en) 2019-12-19 2020-02-05 Gw Res Ltd Oral cannabinoid formulations
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
US11409517B2 (en) * 2020-06-08 2022-08-09 Microsoft Technology Licensing, Llc Intelligent prefetching for OS components
US20220087951A1 (en) 2020-09-18 2022-03-24 GW Research Limited Use of cannabinoids in the treatment of epilepsy
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations

Also Published As

Publication number Publication date
US11311498B2 (en) 2022-04-26
AU2022202119B2 (en) 2024-03-21
JP7813757B2 (ja) 2026-02-13
US20210093581A1 (en) 2021-04-01
US11766411B2 (en) 2023-09-26
ES2680679T3 (es) 2018-09-10
NZ765231A (en) 2023-12-22
GB201410771D0 (en) 2014-07-30
NZ765223A (en) 2023-12-22
JP6655850B2 (ja) 2020-02-26
AU2020220135A1 (en) 2020-09-03
JP2021181451A (ja) 2021-11-25
JP2022062033A (ja) 2022-04-19
JP2017524672A (ja) 2017-08-31
MX2020003182A (es) 2022-04-25
JP7371139B2 (ja) 2023-10-30
JP2020079265A (ja) 2020-05-28
US20210401771A1 (en) 2021-12-30
US20170181982A1 (en) 2017-06-29
PL3157512T3 (pl) 2019-02-28
US20170246121A1 (en) 2017-08-31
CA2952858A1 (en) 2015-12-23
US11154516B2 (en) 2021-10-26
US11963937B2 (en) 2024-04-23
CA2952994C (en) 2023-03-14
JP7010915B2 (ja) 2022-01-26
GB2530001B (en) 2019-01-16
MX2022004851A (es) 2022-05-13
US20150359756A1 (en) 2015-12-17
EP3157511A1 (en) 2017-04-26
AU2015275886A1 (en) 2017-01-12
CA3157008A1 (en) 2015-12-23
US10603288B2 (en) 2020-03-31
JP2017519758A (ja) 2017-07-20
EP3157512B1 (en) 2018-04-25
US20200368179A1 (en) 2020-11-26
ES2680656T3 (es) 2018-09-10
BR112016029498A2 (pt) 2017-08-22
AU2024204928A1 (en) 2024-08-08
US20150359755A1 (en) 2015-12-17
NZ727509A (en) 2023-12-22
JP7238037B2 (ja) 2023-03-13
MX373797B (es) 2020-03-24
MX391834B (es) 2025-03-21
US20170172940A1 (en) 2017-06-22
CA2952858C (en) 2022-10-11
AU2024204928B2 (en) 2026-02-12
MX2019008337A (es) 2019-09-06
AU2024204208A1 (en) 2024-07-11
AU2015275887A1 (en) 2017-01-12
GB2530001A (en) 2016-03-16
US9474726B2 (en) 2016-10-25
US9956183B2 (en) 2018-05-01
MX2022008278A (es) 2022-08-04
PL3157511T3 (pl) 2019-02-28
US9956185B2 (en) 2018-05-01
EP3157511B1 (en) 2018-04-25
JP7712968B2 (ja) 2025-07-24
US20220202738A1 (en) 2022-06-30
JP2020059723A (ja) 2020-04-16
JP6919000B2 (ja) 2021-08-11
GB2531093A (en) 2016-04-13
MX393712B (es) 2025-03-24
JP2023061964A (ja) 2023-05-02
AU2022209295B2 (en) 2024-04-18
MX2016016460A (es) 2017-04-06
WO2015193668A1 (en) 2015-12-23
US20200179303A1 (en) 2020-06-11
US20170173043A1 (en) 2017-06-22
US9949936B2 (en) 2018-04-24
US9956186B2 (en) 2018-05-01
MX2016016459A (es) 2017-04-06
BR112016029506A2 (pt) 2017-08-22
AU2022202119A1 (en) 2022-04-14
EP3157512A1 (en) 2017-04-26
US9956184B2 (en) 2018-05-01
AU2020217417A1 (en) 2020-09-03
US20170172939A1 (en) 2017-06-22
US20240165048A1 (en) 2024-05-23
US20230301936A1 (en) 2023-09-28
US9949937B2 (en) 2018-04-24
AU2020220135C1 (en) 2024-12-05
US20180338931A1 (en) 2018-11-29
NZ727511A (en) 2023-12-22
AU2020220135B2 (en) 2022-03-24
CA2952994A1 (en) 2015-12-23
WO2015193667A1 (en) 2015-12-23
US20250345349A1 (en) 2025-11-13
US20220378717A1 (en) 2022-12-01
AU2022209295A1 (en) 2022-08-25
US20170173044A1 (en) 2017-06-22
US11701330B2 (en) 2023-07-18
GB201506550D0 (en) 2015-06-03
JP6654282B2 (ja) 2020-02-26
JP2024020210A (ja) 2024-02-14

Similar Documents

Publication Publication Date Title
MX2019008337A (es) Uso de cannabinoides para el tratamiento de epilepsia.
MX2020006951A (es) Uso de cannabinoides en el tratamiento de epilepsia.
CY1123459T1 (el) Χρηση των κανναβινοειδων στη θεραπεια του συμπλεγματος οζωδους σκληρυνσης
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
DOP2018000026A (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
CL2016003056A1 (es) Dinucleótidos ciclicos moduladores de sting; composición y combinación farmacéutica que los comprende y uso de los mismos para el tratamiento de enfermedades tales como inflamación, enfermedades alérgicas y autoinmunes, enfermedades infecciosas y cancer.
MX2015016100A (es) Inhibidores de criopirina para prevenir y tratar la inflamacion.
MX373132B (es) Suplemento a base de teacrina y método de uso del mismo.
GT201400275A (es) Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huèrfano rory
AR089993A1 (es) Macrociclos peptidomimeticos
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
NI201400042A (es) 2 - tiopirimidinonas
MX352727B (es) Tratamiento de trastorno autoinmune al usar agonistas de rxr.
MX2014011855A (es) Sistemas y metodos para tratar una respuesta farmacodinamica adversa inducida por opioides.
CL2016002532A1 (es) Compuestos derivados de diheterociclo enlazado a cicloalquilo con actividad inhibidora de gls1 uso en el tratamiento de crecimiento celular anormal, tal como cáncer composición farmacéutica que los contiene
MX376887B (es) Separadores para implantes mamarios para el tratamiento de infecciones periprosteticas de los implantes mamarios.
CL2015001481A1 (es) Uso de extracto bacopa monnieri
AR082436A1 (es) Uso de teriflunomida para tratar la esclerosis multiple
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.
MX2019015273A (es) Moduladores de alfa-sinucleinca.
MX2013011184A (es) Composiciones y metodos para tratar, diagnosticar y vigilar enfermedades.
NZ768000A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
UY35443A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina

Legal Events

Date Code Title Description
FG Grant or registration